The world of DNA testing is changing fast and the race is on to provide cheap, quick genetic diagnoses for patients. Symon Cotton, Head of Life Sciences takes a look at the opportunities on offer for companies working in this dynamic field.
Global pharma is hitting a major fork in the road, and one way leads to failure. For me, it’s vital that the industry comes together to grasp the once-in-a-generation opportunity that emergent technology is offering.
Founders of early-stage start-ups are passionate, driven and optimistic. So, as they embark on the mission to sell their vision, they should accentuate the positive and keep negative thoughts of risk to the back of their mind, right? Wrong.
How do we ensure that not only the rich benefit from cell and gene therapy? Rob Collison of Cambridge Consultants says: It’s about more than cutting costs
The future promises a digitally connected healthcare system that empowers both patients and carers alike. So, what’s the next step for pharma companies and device developers with ambitions in the space?
The current state of in vitro diagnostics is no longer fit for purpose. Inadequate procedures mean that critical insights are often missed, while expenditure statistics on both sides of the Atlantic reveal lagging levels of investment.